BIOCRYST PHARMACEUTICALS INC (BCRX)
US09058V1035 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 110.64M | 304.80M | 504.40M | 272.10M | 114.20M | |||
| Marketable Securities | 278.34M | 119.50M | 3.20M | 28.20M | 22.10M | |||
| Receivables | 56.95M | 50.60M | 29.40M | 8.60M | 22.10M | |||
| Inventories | 28.68M | 27.50M | 15.80M | 7.00M | 0.00 | |||
| Other Current Assets | 21.35M | 14.10M | 13.30M | 7.70M | 6.00M | |||
| Total Current Assets | 495.97M | 516.50M | 566.10M | 323.80M | 164.30M | |||
| Non-Current Assets | ||||||||
| PPE Net | 20.91M | 15.40M | 15.20M | 10.90M | 10.90M | |||
| Investments And Advances | 0.00 | 18.10M | 6.80M | N/A | 0.00 | |||
| Other Non-Current Assets | 80.00K | N/A | N/A | N/A | N/A | |||
| Total Non-Current Assets | 20.99M | 33.50M | 22.10M | 10.90M | 11.00M | |||
| TOTAL ASSETS | 516.96M | 550.00M | 588.20M | 334.70M | 175.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 30.00M | 29.60M | |||
| Current Portion Of LT Debt. | 25.16M | N/A | N/A | 0.00 | 9.00M | |||
| Accrued Expenses | 103.94M | 89.90M | 74.50M | 56.80M | 37.60M | |||
| Accounts Payable | 20.89M | 14.40M | 27.80M | 18.70M | 14.00M | |||
| Other Current Liabilities | 0.00 | 1.20M | 1.40M | 200.00K | 2.10M | |||
| Total Current Liabilities | 149.99M | 105.50M | 103.70M | 105.70M | 92.30M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 814.11M | 733.30M | 585.50M | 244.50M | 41.30M | |||
| Other Non-Current Liabilities | 8.39M | 5.80M | 6.00M | 3.90M | 3.40M | |||
| Total Non-Current Liabilities | 822.50M | 739.10M | 591.40M | 248.30M | 44.70M | |||
| TOTAL LIABILITIES | 972.49M | 844.60M | 695.10M | 354.00M | 137.00M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.68B | -1.45B | -1.21B | -1.02B | -840.60M | |||
| Additional Paid In Capital | 1.22B | 1.16B | 1.10B | 1.00B | 877.30M | |||
| Common Shares | 2.06M | 1.90M | 1.80M | 1.80M | 1.50M | |||
| Other Shareholders' Equity | 1.34M | 0.00 | 200.00K | 0.00 | 0.00 | |||
| Shares Outstanding | 205.77M | 187.90M | 184.40M | 176.90M | 154.10M | |||
| Tangible Book Value per Share | -2.21 | -1.57 | -0.58 | -0.11 | 0.25 | |||
| Total Shareholders' Equity | -455.53M | -294.60M | -107.00M | -19.30M | 38.30M | |||
| TOTAL LIABILITIES AND EQUITY | 516.96M | 550.00M | 588.20M | 334.70M | 175.30M | |||
| Statistics | ||||||||
| Debt/Equity | -1.79 | -2.49 | -5.47 | -14.22 | 1.85 | |||
| Current Ratio | 3.31 | 4.90 | 5.46 | 3.06 | 1.78 | |||
| Return On Assets (ROA) | -43.82% | -44.93% | -31.30% | -54.62% | -62.12% | |||
| Return On Equity (ROE) | N/A | N/A | N/A | N/A | -284.33% | |||
All data in USD